Ginkgo Biloba: Benefits, Evidence, Dosing & Side Effects
Disclaimer: This article is for educational purposes only and should not replace professional medical advice. Consult a healthcare provider before starting any new supplement, especially if you take medications or have existing health conditions.
Overview
Ginkgo biloba is one of the oldest living tree species and has become one of the most widely studied botanical supplements in the world. The standardized extract known as EGb 761 contains 24% flavone glycosides and 6% terpene lactones—the bioactive compounds responsible for its health-supporting properties.
As a nootropic supplement, ginkgo biloba is primarily used to support cognitive function, memory, and cerebral circulation. The evidence base is strongest for age-related cognitive decline and early-stage dementia, though research has explored its effects across numerous health domains including cardiovascular health, mood, inflammation, and joint health.
The supplement is available orally and is generally well-tolerated in healthy adults, with a favorable long-term safety profile when using standardized preparations. However, its antiplatelet activity makes it important to understand potential bleeding risks, particularly when combined with blood-thinning medications.
How It Works: Mechanisms of Action
Ginkgo biloba's effects on health are driven by multiple overlapping mechanisms working synergistically:
Antioxidant Protection
The flavonoid compounds in EGb 761—including quercetin and kaempferol—act as potent antioxidants, neutralizing reactive oxygen species (ROS) that contribute to aging and cellular damage. These compounds protect mitochondrial function in neurons, which is critical for maintaining cognitive energy and preventing neurodegeneration.
Improved Blood Flow
Terpene lactones (ginkgolides A, B, C, and bilobalide) antagonize platelet-activating factor (PAF), reducing platelet aggregation and improving microcirculation throughout the body. This mechanism increases cerebral blood flow via vasodilation, delivering more oxygen and nutrients to brain tissue.
Neurotransmitter Modulation
Beyond circulation and antioxidant effects, ginkgo modulates multiple neurotransmitter systems including acetylcholine and serotonin, which are essential for memory formation, mood regulation, and cognitive processing.
Anti-inflammatory Effects
Ginkgo's bioactive compounds downregulate inflammatory pathways (PI3K/AKT/NF-κB) and reduce production of pro-inflammatory mediators like PGE2 and nitric oxide (NO), contributing to systemic anti-inflammatory effects.
Evidence by Health Goal
Cognition & Brain Function
Evidence Tier: 3 (Probable Efficacy)
Ginkgo biloba shows consistent benefits for cognitive function in dementia patients, though evidence in healthy individuals is absent.
In dementia patients (n=1,628 across multiple RCTs), EGb 761 at 240 mg/day produced significant improvements across all cognitive domains (p<0.001), including behavioral and psychological symptoms, activities of daily living, and quality of life over 22+ weeks of treatment.
However, this benefit does not extend to healthy individuals. A meta-analysis of 1,132 healthy participants showed no significant effect on memory (d=-0.04), executive function (d=-0.05), or attention (d=-0.08), regardless of age, duration, dose, or sample size. This suggests ginkgo's cognitive benefits are specific to those with existing cognitive impairment.
Mood & Stress
Evidence Tier: 3 (Probable Efficacy)
Multiple RCTs and meta-analyses support ginkgo's use for anxiety and stress-related mood symptoms, though effect sizes vary across studies.
A Bayesian network meta-analysis of 29 anxiety trials found ginkgo biloba reduced Hamilton Anxiety Rating Scale (HAMA) scores by 4.63 points versus placebo. In a double-blind RCT with 107 participants over 4 weeks, EGb 761 at 480 mg daily reduced HAMA scores by 14.3 ± 8.1 compared to 7.8 ± 9.2 for placebo (p=0.0003), with a clear dose-response trend (p=0.003).
Sleep
Evidence Tier: 2 (Limited Evidence)
Ginkgo has been studied for sleep primarily as an adjunctive treatment in insomnia, but evidence is limited. No dedicated, high-quality RCTs specifically testing ginkgo for sleep as a primary outcome have demonstrated significant benefits.
A small RCT in 10 healthy volunteers found no significant differences in REM sleep latency, sleep efficiency, or other polysomnographic measures after a single 240 mg dose compared to placebo. Observational data from a real-world cohort of 1,067 insomnia patients found ginkgo was the third most frequently used traditional Chinese medicine (14.71% of cases), though this reflects use frequency rather than efficacy.
Fat Loss
Evidence Tier: 3 (Probable Efficacy)
Ginkgo shows modest effects on body composition through multiple mechanisms including pancreatic lipase inhibition and lipid metabolism regulation, supported by 2-3 human RCTs.
In a 90-day RCT with 60 type 2 diabetes patients taking 120 mg/day of ginkgo extract as adjuvant to metformin, BMI was reduced by 2.4 kg/m² (from 34.0±6.0 to 31.6±5.1, p<0.001), and waist circumference decreased by 3.4 cm (from 106.0±10.9 to 102.6±10.5 cm, p<0.001). However, these results are limited by small sample sizes and lack of independent replication.
Muscle Growth
Evidence Tier: 1 (No Meaningful Evidence—Potential Harm)
Ginkgo biloba has not been studied for muscle growth in humans. The only direct evidence actually suggests harm: ginkgolic acid, a component of ginkgo, significantly inhibited C2C12 myoblast viability and colony formation in a dose-dependent manner in vitro. It also reduced expression of myogenic markers including myosin-heavy chain, MyoD1, and myogenin, and suppressed myotube formation entirely.
If your goal is muscle building, ginkgo is not an appropriate choice and may actually impair myogenic processes.
Injury Recovery
Evidence Tier: 3 (Probable Efficacy)
Ginkgo shows probable efficacy for injury recovery, particularly for neurological injuries and stroke recovery, though evidence is limited by small human sample sizes and predominance of animal data.
A meta-analysis of 13 RCTs (n=1,260) examining ischemic stroke recovery found ginkgo reduced National Institutes of Health Stroke Scale (NIHSS) scores by 3.89 points and improved Barthel Index scores by 11.30 points, indicating improved neurological function and self-care ability.
In animal models, novel ginkgo extract significantly reduced infarct volume at 1, 3, and 14 days post-stroke in rats with middle cerebral artery occlusion and enhanced myelin integrity at 28 days.
Joint Health & Osteoarthritis
Evidence Tier: 3 (Probable Efficacy)
EGb 761 and its bioactive compounds (ginkgetin and isoginkgetin) show probable efficacy for osteoarthritis through anti-inflammatory and chondroprotective mechanisms.
In vitro studies show EGb 761 dose-dependently reduced MMP-3 (a cartilage-degrading enzyme) mRNA and protein expression in IL-1β-stimulated rat chondrocytes, with high-dose EGb showing better efficacy than dexamethasone. Ginkgetin significantly inhibited IL-1β-induced production of inflammatory mediators (PGE2 and NO) and attenuated the PI3K/AKT/NF-κB pathway in human osteoarthritis chondrocytes.
Anti-Inflammation
Evidence Tier: 3 (Probable Efficacy)
Ginkgo biloba reduces inflammatory markers in human clinical trials with statistically significant effects, though evidence is limited to small-to-moderate sample sizes.
A meta-analysis of 17 RCTs (n=1,104) found ginkgo reduced:
- C-reactive protein (CRP) by 1.5 mg/L (95% CI: −2.16, −0.85, p<0.001)
- Interleukin-6 (IL-6) by 16.86 pg/mL (p<0.001)
- Tumor necrosis factor-alpha (TNF-α) by 4.19 pg/mL (p<0.001)
Ginkgo was more effective in participants with baseline CRP ≥3 mg/L and at doses below 500 mg/day.
Heart Health
Evidence Tier: 3 (Probable Efficacy)
Ginkgo shows probable cardiovascular benefits, particularly for myocardial ischemia and blood rheology in diabetic patients, though large-scale human RCT data is limited.
In type 2 diabetic patients across 13 RCTs (n=1,573), ginkgo reduced plasma viscosity (SMD=-0.91) and improved ankle-brachial index (SMD=0.71), indicating improved peripheral blood flow. In animal models, EGb 761 reduced myocardial infarct size and cardiac markers (CK-MB, LDH, troponin T) at doses of 20-40 mg/kg.
Liver Health
Evidence Tier: 3 (Probable Efficacy)
Ginkgo shows probable hepatoprotective effects in animal studies and limited human evidence, though efficacy in humans is not conclusively proven.
In rats exposed to arsenite, ginkgo extract (10 mg/kg for 1 month) significantly reduced hepatocyte senescence markers (p16, p-p53), inflammatory cytokines (IL-1β, IL-6, TNF-α), and oxidative damage (MDA, SOD, GPx) compared to controls.
In mice treated with sodium metabisulfite (a hepatotoxin), ginkgo (100 mg/kg/day) significantly reduced serum liver enzymes (AST, ALT, alkaline phosphatase, bilirubin) and restored reduced glutathione (GSH) levels across liver and multiple tissues.
Immune Support
Evidence Tier: 3 (Probable Efficacy)
Ginkgo shows probable immunomodulatory effects, particularly in restoring T-cell balance and reducing inflammatory markers in specific disease populations.
In arsenicosis patients (n=39 ginkgo, n=35 placebo, 3-month follow-up), ginkgo upregulated regulatory T cells (Treg) and IL-10 levels while downregulating pro-inflammatory Th17 cells, IL-17A, and RORγt expression.
In Alzheimer's disease patients (n=101), ginkgo decreased TNF-α, IFN-γ, and IL-10 production and increased IL-15 and IL-1β, with more pronounced immunomodulatory effects in women.
Energy
Evidence Tier: 2 (Limited Evidence)
Ginkgo shows plausible mechanisms for supporting energy through mitochondrial support and antioxidant effects, but no human RCT evidence specifically demonstrates efficacy for energy or fatigue.
In a yeast model, ginkgo extended chronological lifespan by 73% and reduced ROS by 66%. A four-compound cocktail derived from ginkgo (quercetin, rutin, ginkgolide B, isorhamnetin) extended lifespan 40% with 46% ROS reduction. In a pilot cardiovascular study (n=8), ginkgo increased cAMP by 37.5% and cGMP by 27.7% after 2 months.
Longevity
Evidence Tier: 4 (Strong Evidence for Cognitive Benefits)
EGb 761 at 240 mg/day demonstrates clinically meaningful improvements in cognitive function and activities of daily living in people with cognitive impairment and dementia, though proven lifespan extension in humans has not been established.
Meta-analyses of 9 RCTs (2,561 patients) showed EGb 761 improved cognition versus placebo with a weighted mean difference of -2.86 (95% CI -3.18 to -2.54), improved activities of daily living (SMD -0.36), and improved global clinician impression (OR 1.88).
Skin & Hair
Evidence Tier: 2 (Limited Evidence)
Ginkgo shows emerging promise for skin and hair health, particularly for vitiligo, but robust human clinical evidence remains limited.
A meta-analysis of 15 clinical trials found moderate evidence that ginkgo monotherapy can be useful for vitiligo, with weak-to-moderate support for use with phototherapy. However, other clinical trials failed to show reproducible results, indicating inconsistent efficacy.
Sexual Health
Evidence Tier: 3 (Modest Efficacy)
Ginkgo shows modest efficacy for sexual health, primarily in antidepressant-induced sexual dysfunction and female sexual desire.
An open-label trial reported 84% effectiveness for antidepressant-induced sexual dysfunction (91% in women, 76% in men; n=63). A triple-blind RCT found significant improvement in sexual desire in postmenopausal women with 120-240 mg daily ginkgo versus placebo (p=0.02; n=80).
Athletic Performance
Evidence Tier: 2 (Limited Evidence)
Ginkgo has been studied for athletic performance with mixed results. Two studies show modest improvements in aerobic performance, but evidence is limited by small sample sizes and lack of independent replication.
Six-week ginkgo supplementation (160 mg/day) in physically active men (n=9) produced marginal improvements in VO₂max and increased exercise-induced brain-derived neurotrophic factor (BDNF) production. Seven-week combined rhodiola-ginkgo supplementation (270 mg herbal extracts daily) in 67 healthy young males increased VO₂max significantly more than placebo (p=0.020) and prevented stress-induced cortisol elevation and testosterone/cortisol ratio decline.
Gut Health
Evidence Tier: 2 (Limited Evidence)
Ginkgo shows plausible mechanisms for supporting gut health through microbiota modulation and anti-inflammatory effects, but evidence comes almost entirely from animal studies.
In laying hens with high-fat diet-induced fatty liver disease, ginkgo elevated cecal Megasphaera abundance and significantly increased total short-chain fatty acids (SCFAs), acetate, and propionate production. In vitro studies show ginkgo significantly attenuated hyperglycemia-induced enteric glial cell cytotoxicity and apoptosis.
Hormonal Balance
Evidence Tier: 2 (Limited Evidence)
Ginkgo shows plausible hormonal effects based on limited human data, but efficacy for hormonal health is not conclusively proven.
In cultured human ovarian granulosa cells, ginkgo extract suppressed progesterone, IGF-I, and oxytocin release while promoting prostaglandin F. EGb 761 inhibited aromatase (CYP19) activity and reduced 17β-estradiol levels in aromatase-overexpressing breast cancer cells in vitro and reduced tumor size in animal xenograft models.
Dosing Protocols
The standard effective dose of ginkgo biloba extract (EGb 761) is 120-240 mg twice daily taken orally. Most clinical trials showing cognitive benefits in dementia patients used 240 mg/day (120 mg twice daily).
For anxiety and mood support, studies have used doses ranging from 240-480 mg/day, with evidence of a dose-response relationship. For cardiovascular and anti-inflammatory benefits, doses have typically ranged from 120-240 mg/day.
Important notes:
- Ginkgo is best taken consistently over time rather than as needed; cognitive benefits typically emerge after several weeks of regular use
- Taking ginkgo with food may reduce gastrointestinal side effects
- Raw ginkgo seeds and non-standardized preparations should be avoided entirely, as they can be toxic
- Always use standardized extracts (EGb 761 or equivalent) with verified concentrations of flavone glycosides (24%) and terpene lactones (6%)
Side Effects & Safety
Ginkgo biloba is generally well-tolerated in healthy adults at standardized doses up to 240 mg/day, with a favorable long-term safety record across multiple large trials. However, side effects do occur in some individuals:
Common Side Effects
- Headache (particularly during initial weeks of use)
- Gastrointestinal discomfort including nausea and mild diarrhea
- Dizziness or lightheadedness (especially at higher doses)
- Skin hypersensitivity reactions in individuals with allergies to Anacardiaceae family plants
Bleeding Risk (Critical)
The most significant safety concern is ginkgo's antiplatelet activity, which poses a